TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07363590: A Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1045 in Participants With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 21 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT07363590 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07363590 Rescue Dossier →